Treatment with Oseltamivir in Early Suspected Cases of COVID19
Journal: Medical Journal of Clinical Trials & Case Studies (Vol.4, No. 1)Publication Date: 2020-08-19
Authors : Rawa Jaafar Kadhim AA;
Page : 1-3
Keywords : Oseltamivir; Neuraminidase Inhibitor; Influenza; Prophylaxis; Tamiflu;
Abstract
Oseltamivir (Tamiflu), a neuraminidase inhibitor, an antiviral medication. Although of its effectiveness, still the fear of Tamiflu resistance is concerning. Tamiflu is available in limited pharmacies with an expensive price. It is available in hospitals for influenza after throat swab confirmation. Tamiflu is given as trials to give prophylaxis to COVID19 as there is no resistance to it yet in Iraq due to its limited use. This is a descriptive study, included 37 patients attended to Al-Dora Family Medical Centre from 1st to 31 of December. The cases ranged from 7 years old to 75 years old, presented with various symptoms included shortness of breath, fever, headache, diarrhea, malaise, chest pain, shivering, and dry cough. The study gives a conclusion that Tamiflu may have a role in prophylaxis against covid19 especially in countries with no resistance to it
Other Latest Articles
- Comparative Analysis of Corporate Cultures of Ukraine and Poland: Substantiation Methodology, Theoretical Significance, Practical Conclusions
- Regulatory Support and Institutions for the Transformation of Enterprises to the Digital Economy
- Development of the Smart Specialisation Concept: Theoretical Aspects
- Innovative Development of Ukrainian Enterprises as a Tool for Investment Attraction
- Problems of Providing Regions of Ukraine with Labor as a Risk for Post-War Recovery
Last modified: 2023-07-18 19:44:03